Renaissance Technologies LLC Increases Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Renaissance Technologies LLC increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 56.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 837,200 shares of the company's stock after purchasing an additional 300,800 shares during the quarter. Renaissance Technologies LLC owned 2.29% of iTeos Therapeutics worth $6,430,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ITOS. State Street Corp increased its holdings in iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company's stock valued at $12,000,000 after purchasing an additional 211,452 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of iTeos Therapeutics by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock valued at $4,771,000 after buying an additional 5,368 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock valued at $6,540,000 after buying an additional 20,092 shares during the period. Empowered Funds LLC lifted its stake in iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock worth $530,000 after acquiring an additional 3,305 shares in the last quarter. Finally, Virtu Financial LLC boosted its holdings in iTeos Therapeutics by 84.3% during the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock valued at $142,000 after acquiring an additional 8,460 shares during the period. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ITOS. HC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 6th. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company cut their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS traded up $0.09 on Thursday, hitting $7.24. 54,933 shares of the company's stock were exchanged, compared to its average volume of 352,900. The firm's 50-day moving average is $6.59 and its 200 day moving average is $7.65. The company has a market capitalization of $276.52 million, a PE ratio of -2.30 and a beta of 1.43. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.13. On average, analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.